May 16, 2017 – Cynvenio announces the release of its ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 genes known to be altered in lung cancer, this new test is designed to quickly and accurately identify tumor-related genetic mutations that can be treated with targeted therapies.
April 28, 2017 – Cynvenio in partnership with TME Research announced the launch of a new neoadjuvant breast cancer monitoring (NEAT) study. The multi-center registry study will include at least 10 centers and over 150 patients to be monitored over two years with Cynvenio’s ClearID Breast Cancer blood test.
April 3, 2017 – Cynvenio today announced the immediate availability of two new antibody-based capture kits consisting of EGFR (epidermal growth factor receptor) and PSMA (prostate specific membrane antigen)
February 10, 2017 – Cynvenio Biosystems will feature its LiquidBiopsy rare cell isolation platform at Molecular Med Tri-Con 2017, February 19-24, 2017 in San Francisco.
August 11, 2016 - Article in Clinical Lab Products (CLP) magazine by Cynvenio Chief Science Officer, Paul Dempsey, PhD, discussing improvements in liquid biopsy techniques and the analysis of rare cancer-derived events present among normal cells or DNA.
July 12, 2016 - BioTech Nation interview with Dr. Paul Dempsey about Cynvenio's technology and the ongoing clinical study of women with breast cancer.
June 20, 2016 - An Interview with Paul W. Dempsey, PhD, and Paul Y. Song, MD, of Cynvenio.
May 25, 2016 - Jim Cramer interviews Thermo Fisher Scientific CEO, Marc Casper. In this segment, Casper discusses Cynvenio and LiquidBiopsy.
May 9, 2016 - Article published by Clinical Lab Products discussing the results of Cynvenio's study.
April 5, 2016 — Molecular diagnostic approaches to cancer detection and monitoring can benefit from a multiple-template strategy that analyzes DNA from circulating tumor cells (ctcDNA) and circulating cell free DNA (ccfDNA) in blood, as well as from tissue biopsies, according to new NCI-supported clinical trial published by scientists from Cynvenio Biosystems, Inc., and collaborators. The new research was published online in the journal Oncotarget.
April 1, 2016 - Genome web article highlighting a trial by researchers at Mount Sinai to evaluate the genomic profiles of ctDNA and CTCs as well as phenotypic features of CTCs in patients with triple negative breast cancer to study the relationships between the two and how they correlate with disease. The group will use Cynvenio's LiquidBiopsy microfluidic system to isolate CTCs, ctDNA, and germline DNA.
February 10, 2016 – Cynvenio announces the availability of the Concordia™ cell-free DNA (cfDNA) purification sample preparation upgrade for its multi-template analysis LiquidBiopsy® platform. When coupled with Thermo Fisher Scientific’s Ion Torrent™ next-generation sequencing (NGS) systems, Cynvenio’s workflow provides a comprehensive molecular characterization of tumor cell DNA for cancer research samples from a standard blood draw.
December 28, 2015 – Cynvenio Biosystems, Inc. and ATGen Global, a Korea-based biotech company, announced the launch of a pilot study to evaluate a new method for early detection of cancer in women who have completed treatment for triple-negative breast cancer (TNBC) and show no radiographic signs of metastases.
December 2, 2015 – Cynvenio announces that it has entered into a strategic collaboration with the Institute of Regional Health Research for the Region of Southern Denmark at the University of Southern Denmark to conduct a wide array of clinical cancer trials using Cynvenio’s Triple Play LiquidBiopsy® platform.
October 1, 2015 – Cynvenio Biosystems, Inc. announces that it has developed, validated, and fully implemented a PD-L1 (Programmed Death-Ligand 1) assay for circulating tumor cells (CTCs) obtained via its LiquidBiopsy® technology for several tumor subtypes.
September 8, 2015 – Cynvenio Biosystems announces that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its laboratory. Cynvenio has been certified by CLIA, the U.S. Clinical Laboratory Improvement Amendments, since 2013.
September 3, 2015 – Cynvenio Biosystems, Inc. today announced it has hired Paul Y. Song, M.D as Chief Medical Officer to oversee translational and clinical research programs at Cynvenio.
June 16, 2015 – Cynvenio Biosystems, Inc. announces the completion a $25.5 million Series B equity financing. Proceeds from the investment will be used to advance the company’s clinical development and commercialization programs. The Series B round was led by Livzon Pharmaceutical Group, Inc. a diversified drug, diagnostics and healthcare company based in Zhuhai, P.R. China. Other investors included Greenwoods Private Equity Funds (Shanghai) and Syno Capital (New York), among others.
April 22, 2015 - From the AACR 2015 exhibit floor, video interviews discussing the advantages of LiquidBiopsy system and workflow. From collection and stabilization to excellent recovery and downstream analysis this system isolates both cell-free DNA (cfDNA) and circulating tumor cells (CTCs) from a single whole-blood sample.
April 20, 2015 –Thermo Fisher Scientific unveils new innovations for research aimed at addressing the growing need for early detection, better prognosis, and more effective cancer treatments in the future. These new products, including Cynvenio's LiquidBiopsy platform, are being featured at the American Association for Cancer Research (AACR) 2015 Annual Meeting, booth #1501 in Philadelphia, Pa.